[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"head-and-neck-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:head-and-neck-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100650023","phase-1-study-evaluating-the-safety-and-feasibility-of-panitumumab-irdye800-and-18fnota-aby-030-for-targeted-dual-modality-imaging-tdmi-in-head-and-neck-squamous-cell-carcinoma-100650023",false,"NCT07741643","Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma","Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Subjects diagnosed with any T stage or N stage squamous cell carcinoma and any subsite within the head and neck that are scheduled to undergo surgical resection and neck dissection. Subjects with recurrent disease or a new primary will be allowed.\n3. Have acceptable hematologic status, kidney function, and liver function including the following clinical results:\n\n   * Hemoglobin ≥ 9 gm\u002FdL\n   * White blood cell count \\> 3000\u002Fmm3\n   * Platelet count ≥ 100,000\u002Fmm3\n   * Serum creatinine ≤ 1.5 times upper reference range\n   * Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.\n2. Evidence of QTcF prolongation on ECG within 30 days of pan800 administration (greater than 480 ms).\n3. History of infusion reactions to monoclonal antibody therapies.\n4. History of allergies to iodine.\n5. Pregnant or breastfeeding.\n6. Magnesium or phosphorus lower than the normal institutional values and the patient is symptomatic.\n7. Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.\n8. Subjects with history or evidence of interstitial pneumonitis or pulmonary fibrosis.\n9. Severe renal disease or anuria.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and\\[18F\\]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during surgery in adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled for tumor removal and neck dissection.\n\nThe main questions it aims to answer are:\n\n* Is the combination of Pan800 and \\[18F\\]NOTA-ABY-030 safe and well tolerated in patients undergoing surgery for HNSCC?\n* How accurately can Pan800 and \\[18F\\]NOTA-ABY-030 detect tumor tissue and cancer-positive lymph nodes when compared with final pathology results?\n\nThis is a single-arm, open-label study, so there is no comparison group.\n\nStudy Related Steps:\n\n* Receive an intravenous infusion of Pan800 1-2 days before surgery.\n* Receive an intravenous injection of\\[18F\\]NOTA-ABY-030 on the day of surgery.",[26,27,28,29],"HNSCC,Larynx, Pharynx and Oral Cavity","Squamous Cell Carcinoma","Head and Neck Cancer","Head and Neck Surgery",[31,32,33,34],"SCC","HNSCC","Oral Cavity","Fluorescent Guided Surgery","NOT_YET_RECRUITING","2026-07-29",{"date":38,"type":39},"2026-08-03","ACTUAL",{"date":41,"type":20},"2026-08",{"date":43,"type":20},"2031-07",{"name":45,"class":46},"Vanderbilt-Ingram Cancer Center","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100610896","preoperative-maxillary-nerve-block-and-remifentanil-use-in-septorhinoplasty-100610896","NCT07233538","Preoperative Maxillary Nerve Block and Remifentanil Use in Septorhinoplasty","Effect of Preoperative Ultrasound-guided Bilateral Maxillary Nerve Block Via the Pterygopalatine Fossa on Intraoperative Remifentanil Use in Septorhinoplasty","PRISM","Inclusion Criteria:\n\n* Those with an ASA (American Society of Anesthesiologists) score of I-II\n* Those with a body mass index (BMI) between 18 and 30\n* Those scheduled for elective surgery\n* Those who are fully cooperative Patients who meet the criteria for septorhinoplasty surgery\n\nExclusion Criteria:\n\n* Conditions that constitute a relative contraindication to regional anesthesia (e.g., coagulation disorders, thrombocytopenia, severe valvular heart disease, local infection at the injection site, allergy to local anesthetic agents)\n* International Normalized Ratio (INR) \\> 1.5\n* Facial paralysis or a history of facial paralysis\n* History of central nervous system vascular disease\n* Presence of neuropathy\n* History of surgery in the region where the block will be performed\n* American Society of Anesthesiologists (ASA) physical status classification of III or higher\n* Patients who do not want to participate in the study\n* Patients with chronic pain or chronic opioid use\n* Patients with alcohol, substance or drug addiction\n* Patients with limited cooperation such as dementia, psychiatric disorders\n* Pregnant and breastfeeding patients will be excluded from the study.\n* Patients who cannot communicate in their native language will be excluded from the study","65 Years",{"count":57,"type":20},90,[59],"NA","Septorhinoplasty is generally a prolonged surgical procedure that frequently involves osteotomy, which may lead to increased intraoperative remifentanil requirements. Moreover, it is often associated with significant bleeding due to the dense capillary network of the nasal region, making the maintenance of low-to-normal blood pressure preferable during surgery. Consequently, achieving stable hemodynamics and providing sufficient analgesia throughout the procedure is essential.\n\nThis study aims to evaluate the effects of bilateral maxillary nerve block on intraoperative remifentanil consumption and postoperative analgesic efficacy in patients undergoing Septorhinoplasty. A total of 90 patients will be included in the study. Forty-five patients (Group M) will undergo Septorhinoplasty under general anesthesia combined with bilateral maxillary nerve block, while the remaining 45 patients (Group N) will receive general anesthesia alone.\n\nIn the preoperative phase, a bilateral maxillary nerve block will be performed under ultrasound guidance via the pterygopalatine fossa. During the intraoperative period, total remifentanil consumption will be recorded, alongside assessments of hemodynamic stability, sevoflurane consumption, extubation time, intraoperative bleeding volume, and the satisfaction levels of both the anesthesiologist and the surgeon.\n\nIn the postoperative period, patient satisfaction, pain scores at 0, 1, 2, 4, 6, 12, 18, and 24 hours as well as at 1 month (measured using the Visual Analog Scale - VAS), additional analgesic requirements, and Quality of Recovery-15 (QoR-15) scores (assessed on preoperative day 1, postoperative day 1, and at 1 month) will be evaluated.",[29,62,63,64,65,66],"Plastic Surgery","Rhinoplasty","Pain","Regional Anaesthesia","Nerve Blocks","RECRUITING","2025-11-17",{"date":70,"type":39},"2025-11-18",{"date":72,"type":39},"2025-08-20",{"date":74,"type":20},"2026-12-08",{"name":76,"class":77},"Ankara Etlik City Hospital","OTHER_GOV",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":78},"100575793","fiberoptic-intubation-in-lateral-versus-supine-position-in-pediatrics-undergoing-non-head-and-neck-surgery-100575793","NCT06776900","Fiberoptic Intubation in Lateral Versus Supine Position in Pediatrics Undergoing Non-head-and-neck Surgery","Video-assisted Fiberoptic Intubation in Lateral Versus Supine Position in Pediatrics Undergoing Non-head-and-neck Surgery: a Randomized Controlled Non-inferiority Trial","Inclusion Criteria:\n\n* Children aged 2-10 years old.\n* Both genders.\n* ASA physical status I and II.\n* Elective non-head-and-neck surgeries.\n\nExclusion Criteria:\n\n* Refusal of patients.\n* Head and neck surgeries or with history of previous ones.\n* Head, neck and lung congenital deformities or pathologies.\n* Patients with expected difficult intubation (based on examination).\n* Patients with neuromuscular disorders.\n* Hypoxia: defined as low oxygen saturation (SpO2) ≤ 95% on room air.\n* Trauma patients or patients requiring emergency procedures.","2 Years","10 Years",{"count":89,"type":20},50,[59],"Fiberoptic intubation was first described in the late 1960s and has since become an effective and well-established technique for airway management in awake, sedated, and anesthetized patients. This technique is especially useful in patients with known or suspected difficult airways such as those with limited mouth opening, reduced neck mobility, cervical spine injury, obesity, or an elevated risk for aspiration. The benefits of fiberoptic intubation also include fewer complications such as tooth injury and oropharyngeal bleeding; and the opportunity for optimal positioning of double-lumen tubes in patients undergoing thoracic surgery.\n\nAnesthesiologists may be confronted with situations in which patients in a lateral position during surgery experience an accidental loss of airway patency. Intubation with direct laryngoscopy is more challenging and time-consuming in patients in the lateral position than in the supine position, particularly when there is an abrupt loss of airway patency, as demonstrated by prior research. These observations suggest that there is an unmet need for a reliable method of airway management for patients in the lateral position. Although the airway is of a larger caliber and ventilation renders less peak and better oxygenation when patients are in the lateral position, glottic view was unfavorable for intubation when Macintosh direct laryngoscope was used in this position. This could be the reason why such a procedure is unfamiliar in anesthesia even when it is the most needed in special situations. Flexible fiberoptic intubation in lateral position would be convenient in emergency situations like accidental extubation during surgery or inadequate regional anesthesia requiring general anesthesia. Flexible fiberoptic intubation in lateral position would be of significant assistance in neurosurgical patients especially those with occipital lesions and patients with difficult airway scores with limited mouth opening or neck extension.\n\nAfter thorough literature review, we found that studies comparing flexible video-assisted fiberoptic intubation in the lateral versus supine position in pediatrics are lacking.",[93,29,94],"Video-assisted","Intubation","2025-01-19",{"date":97,"type":39},"2025-01-22",{"date":99,"type":39},"2025-01-18",{"date":101,"type":20},"2025-08",{"name":103,"class":46},"Cairo University"]